United Therapeutics (NASDAQ:UTHR) CEO Martine Rothblatt Sells 8,000 Shares

United Therapeutics CEO Martine Rothblatt sold 8,000 shares at $398.55 each, totaling $3.19 million, reducing her ownership by 98.4% to 130 shares valued at $51,811.50. The transaction was disclosed to the SEC. The company's stock opened at $396.50, with a market cap of $17.89 billion and a P/E ratio of 15.48. Analysts have mixed ratings, with a consensus price target of $438.85, reflecting a "Moderate Buy" rating.

United Therapeutics Corporation (NASDAQ:UTHR - Get Free Report) CEO Martine Rothblatt sold 8,000 shares of the stock in a transaction that occurred on Tuesday, September 9th. The shares were sold at an average price of $398.55, for a total transaction of $3,188,400.00. Following the completion of the sale, the chief executive officer owned 130 shares in the company, valued at $51,811.50. This represents a 98.40% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link.

United Therapeutics Price Performance

The Top 3 Stock Picks at the World’s Greatest Hedge Fund

UTHR stock opened at $396.50 on Thursday. The company's 50 day simple moving average is $314.12 and its 200-day simple moving average is $306.91. The firm has a market capitalization of $17.89 billion, a PE ratio of 15.48, a P/E/G ratio of 6.16 and a beta of 0.62. United Therapeutics Corporation has a 12 month low of $266.98 and a 12 month high of $436.95.

United Therapeutics (NASDAQ:UTHR - Get Free Report) last announced its earnings results on Wednesday, July 30th. The biotechnology company reported $6.41 earnings per share (EPS) for the quarter, missing analysts' consensus estimates of $6.80 by ($0.39). United Therapeutics had a return on equity of 18.73% and a net margin of 40.36%.The firm had revenue of $798.60 million for the quarter, compared to analyst estimates of $802.13 million. During the same quarter last year, the business posted $5.85 EPS. The firm's revenue was up 11.7% compared to the same quarter last year. As a group, sell-side analysts anticipate that United Therapeutics Corporation will post 24.48 earnings per share for the current year.

Hedge Funds Weigh In On United Therapeutics

Liquidia: Court victory the awakening of an industry giant?

Large investors have recently bought and sold shares of the stock. Chung Wu Investment Group LLC purchased a new position in shares of United Therapeutics in the 2nd quarter valued at $29,000. WealthCollab LLC raised its stake in shares of United Therapeutics by 55.9% in the 2nd quarter. WealthCollab LLC now owns 106 shares of the biotechnology company's stock valued at $30,000 after acquiring an additional 38 shares during the period. Rakuten Securities Inc. raised its stake in shares of United Therapeutics by 76.7% in the 2nd quarter. Rakuten Securities Inc. now owns 106 shares of the biotechnology company's stock valued at $30,000 after acquiring an additional 46 shares during the period. SVB Wealth LLC purchased a new position in shares of United Therapeutics in the 1st quarter valued at $32,000. Finally, Geneos Wealth Management Inc. raised its stake in shares of United Therapeutics by 141.7% in the 1st quarter. Geneos Wealth Management Inc. now owns 145 shares of the biotechnology company's stock valued at $45,000 after acquiring an additional 85 shares during the period. Hedge funds and other institutional investors own 94.08% of the company's stock.

Wall Street Analyst Weigh In

A number of analysts recently issued reports on the stock. JPMorgan Chase & Co. decreased their target price on shares of United Therapeutics from $350.00 to $330.00 and set an "overweight" rating on the stock in a research report on Tuesday, July 8th. Bank of America raised their target price on shares of United Therapeutics from $314.00 to $463.00 and gave the stock a "neutral" rating in a research report on Tuesday, September 2nd. UBS Group raised their target price on shares of United Therapeutics from $415.00 to $560.00 and gave the stock a "buy" rating in a research report on Thursday, September 4th. Oppenheimer increased their price target on shares of United Therapeutics from $510.00 to $575.00 and gave the stock an "outperform" rating in a research note on Friday, September 5th. Finally, Jefferies Financial Group increased their price target on shares of United Therapeutics from $432.00 to $564.00 and gave the stock a "buy" rating in a research note on Tuesday, September 2nd. Nine investment analysts have rated the stock with a Buy rating and four have issued a Hold rating to the company's stock. Based on data from MarketBeat.com, the company currently has a consensus rating of "Moderate Buy" and a consensus price target of $438.85.

Analysts Say These 2 Mid-Cap Biotechs Have 2x Potential

Check Out Our Latest Analysis on United Therapeutics

United Therapeutics Company Profile

(Get Free Report)

United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. The company offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients.